review · International Journal of Medical Sciences and Pharma Research
The endothelial glycocalyx serves as a vital protective barrier for vascular health. In sickle cell anaemia, its degradation plays a central role in driving endothelial dysfunction and vaso-occlusive crises. Mechanical shear stress from altered blood flow, alongside oxidative stress caused by chronic inflammation and hemolysis, actively breaks down this protective layer. In addition, specific enzymes including heparanase, hyaluronidase, and matrix metalloproteinases degrade key glycocalyx components. This destruction increases vascular permeability, promotes inflammation, and impairs nitric oxide production, which in turn prompts vasoconstriction and thrombosis. Consequently, sickled red blood cells and other circulating cells adhere and aggregate more easily, triggering painful blockages. Proposed therapeutic strategies seek to preserve or rebuild this barrier using glycocalyx precursors, synthetic mimetics, enzyme inhibitors, antioxidant therapies, and nitric oxide donors to restore vascular stability and reduce crisis frequency.
Sickle cell anaemia causes severe pain and organ damage when blood vessels become blocked during vaso-occlusive crises. Protecting the delicate lining of blood vessels offers a promising route to prevent these dangerous episodes. Clarifying the biological mechanisms behind vessel wall breakdown helps guide the development of targeted therapies that preserve blood flow, reduce vessel inflammation, and improve outcomes for patients living with the condition.
The work highlights therapeutic avenues, including synthetic mimetics, enzyme inhibitors, glycocalyx precursors, and nitric oxide donors, that could be pursued by pharmaceutical and biotechnology developers. These tools aim to mitigate vaso-occlusive crises by maintaining vascular integrity in sickle cell anaemia patients. As the text outlines broad mechanisms and prospective drug categories rather than validated formulations or clinical trials, the identified interventions represent early-stage therapeutic research.
AI-generated from the published abstract. Always read the original work before citing.
The endothelial glycocalyx is a crucial component of vascular homeostasis, acting as a protective barrier and regulator of endothelial function. In sickle cell anemia (SCA), the degradation of the glycocalyx significantly contributes to endothelial dysfunction and the pathogenesis of vaso-occlusive crises (VOCs). This review examines the mechanisms of glycocalyx degradation, including the roles of shear stress, enzymatic activity, and oxidative stress. The breakdown of the glycocalyx leads to increased vascular permeability, enhanced cell adhesion, and impaired nitric oxide (NO) production, all of which exacerbate endothelial dysfunction and promote VOCs. Mechanistically, shear stress and mechanical forces from altered hemodynamics in SCA disrupt the glycocalyx. Enzymes like heparanase, hyaluronidase, and matrix metalloproteinases degrade glycocalyx components, while oxidative stress from chronic inflammation and hemolysis further accelerates this process. The resulting endothelial dysfunction manifests as increased permeability, promoting inflammation and cell adhesion, and reduced NO synthesis, leading to vasoconstriction and thrombosis. This pro-thrombotic environment facilitates the adhesion and aggregation of sickled red blood cells (RBCs) and other circulating cells, driving VOCs. Therapeutic strategies targeting glycocalyx preservation and restoration are critical for mitigating endothelial dysfunction in SCA. Approaches include the use of glycocalyx precursors, synthetic mimetics, antioxidant therapy, enzyme inhibitors, and nitric oxide donors. These therapies aim to restore the glycocalyx, reduce oxidative stress, and improve NO bioavailability, thereby reducing the incidence and severity of VOCs. Continued research into these therapeutic interventions is essential for optimizing treatment and improving clinical outcomes for patients with SCA. Keywords: Glycocalyx, Endothelial Dysfunction, Vaso-Occlusion, Sickle Cell Anemia, Inflammation, Shear Stress, Endothelial Cells
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.22270/ijmspr.v10i2.102
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
